课题基金 / 基金详情

Translational Bioenergetics in Patients with Alcoholic Liver Disease

Translational Bioenergetics in Patients with Alcoholic Liver Disease
酒精性肝病患者的转化生物能学
批准号:
9061506
负责人:
VICTOR M DARLEY-USMAR
金额:
$17.46万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-05-01 至 2018-04-30

项目摘要

项目成果

VICTOR M DARLEY-USMAR的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Alcoholic hepatitis is a syndrome characterized by rapid onset of jaundice, liver failure and the key features of a systemic inflammatory response syndrome. Patients with severe episodes of alcoholic hepatitis have a mortality rate as high as 40-50% 1 month after presentation. The treatment of acute alcoholic hepatitis is a clinical challenge because a) it is difficult to differentiate it from spontaneous decompensation of alcoholic cirrhosis and b) the limited treatment options have variable and unpredictable efficacy. Furthermore, currently- available treatments for alcoholic hepatitis patients with corticosteroids or pentoxifylline provide only about 50% survival benefit. Hence, there is an unmet need of a biomarker for diagnosis of alcoholic hepatitis and predicting its responsiveness to treatment with corticosteroids. Basic research into the pathogenesis of alcoholic liver disease using animal models has identified a number of contributory factors including inflammation, mitochondrial dysfunction and a severe oxidative/nitrative stress. An intrinsic characteristic of pathologies associated with inflammation and metabolic dysfunction is the suppression of the cellular bioenergetics to below the threshold that induces cell death. In this proposal, we will use a novel methodology to assess cellular bioenergetics in the leukocytes isolated from patient's blood and test the hypothesis that this can serve as a biomarker of the severity of alcoholic liver disease. This project builds on the expertise of the PIs in managing alcoholic liver disease patients, biostatistics and the evaluation of mitochondrial dysfunction in disease. We have found that a) bioenergetic health can be defined by an analysis of cellular bioenergetics in blood leukocytes that can be isolated from 20 ml of human blood, b) monocytes show a rapidly developing decrease in bioenergetic health in patients with alcoholic liver disease, and c) the oxidative burs in neutrophils and monocytes can be readily assessed in the same sample and is depressed in alcoholic patients. In this application we will test the hypothesis that alcoholic liver disease patients with severe cellular bioenergetic defects and low oxidative burst activity detectable in monocytes and neutrophils will progress more rapidly to liver failure and be unresponsive to corticosteroid treatment.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Pharmacotherapies for Portal Hypertension: Current Status and Expanding Indications.
门脉高压的药物治疗:现状和扩展适应症。
DOI: 10.1007/s11901-023-00600-z
发表时间: 2023
期刊: Current hepatology reports
影响因子: --
作者: [Elfeki,MohamedA, Singal,AshwaniK, Kamath,PatrickS]
通讯作者: Kamath,PatrickS
Core D: Comparative Mitochondrial Health Assessment Core
Translational Bioenergetics in Patients with Alcoholic Liver Disease
Mitochondrial Bioenergetic Dysfunction and Chlorine Toxicity
Mitochondrial Bioenergetic Dysfunction and Chlorine Toxicity
海外基金